Announcements Trials
Browse Landscape

Phase

Phase 1 18Phase 2 13Phase 1/2 4Phase 3 2

Status

Completed 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Other solid neoplasm 2Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Malignant Solid Tumour 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × ARQ 197 × Clear all
NCT01075048 2021-04-08

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Daiichi Sankyo

Phase 1/2 Completed
131 enrolled 15 charts
Gastrointestinal

Colorectal Neoplasms

NCT01178411 2021-03-10

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Completed
60 enrolled 11 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

NCT02049060 2021-01-22

Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin

Istituto Clinico Humanitas

Phase 1/2 Completed
31 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01611857 2016-11-23

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

SCRI Development Innovations, LLC

Phase 1/2 Completed
49 enrolled 12 charts
GastrointestinalOther solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡